← Eichor
Study identifier: NCT06892171 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Study of the Phenotype of Hereditary Xerocytosis

Condition: Xerocytosis · Phenotype · Genotype  ·  Sponsor: Centre Hospitalier Universitaire, Amiens

PhaseNA
Planned participants20
Who can joinAll sexes, 10 Years to no upper limit
Healthy volunteersNo

About this study

Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.

This description comes directly from the study's public registry record.

Talk to the study team

Loic Garçon, Pr  ·  33+322088371  ·  garcon.loic@chu-amiens.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHRU AmiensAmiens, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06892171